title: In vivo delineation of 5-HT1A receptors in human brain with [18F]MPPF.
abstract: Serotonin-1A (5-hydroxytryptamine-1A [5-HT1A]) receptors have been reported to play an important role in the pathophysiology of a variety of psychiatric and neurodegenerative disorders. Animal experiments have shown that 4-(2'-methoxyphenyl)-1-[2'-(N-2'-pyridinyl)-p-[18F]fluorobenzamido ]ethylpiperazine ([18F]MPPF) may be suitable for 5-HT1A receptor imaging in humans. The aim of this study was to determine if [18F]MPPF can be used for the quantitative analysis of 5-HT1A receptor densities in brain regions of healthy human volunteers.
  
  
  METHODS
  [15O]H2O perfusion scanning was performed before intravenous injection of [18F]MPPF to obtain anatomic information. Cerebral radioactivity was monitored using a PET camera. Plasma metabolites of [18F]MPPF were determined by high-performance liquid chromatography. Binding potentials were calculated using the metabolite-corrected arterial input function and a linear graphic method (Logan-Patlak analysis).
  
  
  RESULTS
  The highest levels of radioactivity were observed in the medial temporal cortex, especially in the hippocampal area. In contrast, the cerebellum and basal ganglia showed low uptake of 18F, in accordance with known 5-HT1A receptor distribution. The calculated binding potentials correlated well with literature values for 5-HT1A receptor densities. The binding potentials for [18F]MPPF were 4-6 times lower than those that have been reported for [carbonyl-1C]-(N-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-N-(2-pyrid yl) cyclohexane-carboxamide (WAY 100635), indicating that [18F]MPPF has a lower in vivo affinity for 5-HT1A receptors.
  
  
  CONCLUSIONS
  These results confirm that [18F]MPPF can be used for the quantitative analysis of 5-HT1A receptor distribution in the living human brain. The rapid dissociation from the receptor makes this ligand a possible candidate to monitor changes in endogenous serotonin levels.
authors.affiliation: PET Center, Groningen University Hospital, The Netherlands.
authors.forename: J
authors.initials: J
authors.lastname: Passchier
authors.forename: A
authors.initials: A
authors.lastname: van Waarde
authors.forename: R M
authors.initials: RM
authors.lastname: Pieterman
authors.forename: P H
authors.initials: PH
authors.lastname: Elsinga
authors.forename: J
authors.initials: J
authors.lastname: Pruim
authors.forename: H N
authors.initials: HN
authors.lastname: Hendrikse
authors.forename: A T
authors.initials: AT
authors.lastname: Willemsen
authors.forename: W
authors.initials: W
authors.lastname: Vaalburg
mesh_terms: D000328:Adult; D000368:Aged; D001921:Brain / Q000378:metabolism*; D002531:Cerebellum / Q000378:metabolism; D005260:Female; D005625:Frontal Lobe / Q000378:metabolism; D006801:Humans; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000493:pharmacokinetics; D011725:Pyridines / Q000493:pharmacokinetics; D011985:Receptors, Serotonin / Q000032:analysis*; D044263:Receptors, Serotonin, 5-HT1; D013702:Temporal Lobe / Q000378:metabolism; D014055:Tomography, Emission-Computed
chemical_list: D010879:Piperazines; D011725:Pyridines; D011985:Receptors, Serotonin; D044263:Receptors, Serotonin, 5-HT1; C416325:4-(2'-methoxyphenyl)-1-(2'-(N-2'-pyridinyl)-p-(18F)fluorobenzamido )ethylpiperazine